Exagen Appoints Dr. Dennis Horvath as CEO
Ticker: XGN · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1274737
| Field | Detail |
|---|---|
| Company | Exagen Inc. (XGN) |
| Form Type | 8-K |
| Filed Date | Apr 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, ceo-appointment, executive-compensation
Related Tickers: EXAGEN
TL;DR
Exagen CEO out, COO Horvath steps up with $400k salary.
AI Summary
Exagen Inc. announced on April 22, 2024, the appointment of Dr. Dennis Horvath as its new Chief Executive Officer and a member of the Board of Directors. Dr. Horvath, who previously served as the company's Chief Operating Officer, will also receive an annual base salary of $400,000. The company also reported the departure of its former CEO, Kamal Singh, effective April 22, 2024.
Why It Matters
The appointment of a new CEO can signal a shift in company strategy and leadership, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes, especially CEO transitions, introduce uncertainty regarding future strategy and execution, which can be a medium-term risk.
Key Numbers
- $400,000 — CEO Salary (Annual base salary for the new CEO, Dr. Dennis Horvath.)
Key Players & Entities
- Exagen Inc. (company) — The company filing the report.
- Dr. Dennis Horvath (person) — Newly appointed Chief Executive Officer and Board Member.
- $400,000 (dollar_amount) — Annual base salary for the new CEO.
- Kamal Singh (person) — Former Chief Executive Officer.
FAQ
Who has been appointed as the new CEO of Exagen Inc.?
Dr. Dennis Horvath has been appointed as the new Chief Executive Officer of Exagen Inc.
What is the annual base salary for the new CEO?
The annual base salary for Dr. Dennis Horvath is $400,000.
When did the leadership change take effect?
The leadership change, including the appointment of Dr. Horvath and the departure of Kamal Singh, took effect on April 22, 2024.
What was Dr. Horvath's previous role at Exagen?
Prior to his appointment as CEO, Dr. Dennis Horvath served as the Chief Operating Officer of Exagen Inc.
Who is the former CEO of Exagen Inc.?
Kamal Singh is the former CEO of Exagen Inc., and his departure was effective April 22, 2024.
Filing Stats: 1,340 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2024-04-26 08:32:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Mar
Filing Documents
- exdx-20240422.htm (8-K) — 43KB
- pressrelease-20240422board.htm (EX-99.1) — 10KB
- 0001274737-24-000030.txt ( ) — 184KB
- exdx-20240422.xsd (EX-101.SCH) — 2KB
- exdx-20240422_lab.xml (EX-101.LAB) — 22KB
- exdx-20240422_pre.xml (EX-101.PRE) — 13KB
- exdx-20240422_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On April 26, 2024, the Company issued a press release announcing the resignations of Mr. Birk, Ms. Johnson and Dr. Pallares as directors and the appointment of Dr. Kahn as a director, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated April 26 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXAGEN INC. Date: April 26, 2024 By: /s/ Kamal Adawi Name: Kamal Adawi Title: Chief Financial Officer